Alumis Inc (ALMS)vsAlnylam Pharmaceuticals Inc (ALNY)
ALMS
Alumis Inc
$23.07
-1.24%
HEALTHCARE · Cap: $3.17B
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 15343% more annual revenue ($3.71B vs $24.05M). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALMS
Avoid24
out of 100
Grade: F
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALMS.
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
Trading at 8.0x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALMS
The strongest argument for ALMS centers on Debt/Equity.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ALMS
The primary concerns for ALMS are Price/Book, Revenue Growth, EPS Growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
ALMS profiles as a value stock while ALNY is a hypergrowth play — different risk/reward profiles.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (49/100 vs 24/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alumis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alumis Inc. (ALMS) is an innovative leader in the development and commercialization of high-performance aluminum products, serving critical sectors such as automotive, aerospace, and construction. The company harnesses proprietary technologies to advance material science while adhering to sustainable manufacturing practices, ensuring minimal environmental impact. Focused on research and development, Alumis is strategically positioned to capitalize on emerging market opportunities and expand its diverse product portfolio. With a commitment to operational excellence and stakeholder value, Alumis aims to sustain long-term growth through continuous innovation.
Visit Website →Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?